626 related articles for article (PubMed ID: 26927950)
1. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.
Curatolo P; Bjørnvold M; Dill PE; Ferreira JC; Feucht M; Hertzberg C; Jansen A; Jóźwiak S; Kingswood JC; Kotulska K; Macaya A; Moavero R; Nabbout R; Zonnenberg BA
Drugs; 2016 Apr; 76(5):551-65. PubMed ID: 26927950
[TBL] [Abstract][Full Text] [Related]
2. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
3. Management of side effects of mTOR inhibitors in tuberous sclerosis patients.
Sadowski K; Kotulska K; Jóźwiak S
Pharmacol Rep; 2016 Jun; 68(3):536-42. PubMed ID: 26891243
[TBL] [Abstract][Full Text] [Related]
4. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.
Budde K; Gaedeke J
Am J Kidney Dis; 2012 Feb; 59(2):276-83. PubMed ID: 22130643
[TBL] [Abstract][Full Text] [Related]
5. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
[TBL] [Abstract][Full Text] [Related]
6. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
Franz DN
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
[TBL] [Abstract][Full Text] [Related]
7. Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex.
Jiang T; Du J; Raynald ; Wang J; Li C
World Neurosurg; 2017 Nov; 107():1053.e1-1053.e6. PubMed ID: 28866062
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study.
Samueli S; Abraham K; Dressler A; Gröppel G; Mühlebner-Fahrngruber A; Scholl T; Kasprian G; Laccone F; Feucht M
Orphanet J Rare Dis; 2016 Nov; 11(1):145. PubMed ID: 27809914
[TBL] [Abstract][Full Text] [Related]
9. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.
Kingswood JC; Jozwiak S; Belousova ED; Frost MD; Kuperman RA; Bebin EM; Korf BR; Flamini JR; Kohrman MH; Sparagana SP; Wu JY; Brechenmacher T; Stein K; Berkowitz N; Bissler JJ; Franz DN
Nephrol Dial Transplant; 2014 Jun; 29(6):1203-10. PubMed ID: 24729041
[TBL] [Abstract][Full Text] [Related]
10. mTOR Inhibitors in Children: Current Indications and Future Directions in Neurology.
Jeong A; Wong M
Curr Neurol Neurosci Rep; 2016 Dec; 16(12):102. PubMed ID: 27815691
[TBL] [Abstract][Full Text] [Related]
11. mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex.
Franz DN; Krueger DA
Am J Med Genet C Semin Med Genet; 2018 Sep; 178(3):365-373. PubMed ID: 30307123
[TBL] [Abstract][Full Text] [Related]
12. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
[TBL] [Abstract][Full Text] [Related]
13. Current Use of mTOR Inhibitors for the Treatment of Subependymal Giant Cell Astrocytomas and Epilepsy in Patients with TSC.
Jancic J; Duric V; Ivancevic N; Nikolic B; van den Anker JN; Samardzic J
Curr Med Chem; 2016; 23(37):4260-4269. PubMed ID: 27739368
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex.
Palavra F; Robalo C; Reis F
Oxid Med Cell Longev; 2017; 2017():9820181. PubMed ID: 28386314
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Curatolo P
Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex.
Samuels JA
Clin J Am Soc Nephrol; 2017 Jul; 12(7):1196-1202. PubMed ID: 28302901
[TBL] [Abstract][Full Text] [Related]
17. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
Somers MJ; Paul E
J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.
Saffari A; Brösse I; Wiemer-Kruel A; Wilken B; Kreuzaler P; Hahn A; Bernhard MK; van Tilburg CM; Hoffmann GF; Gorenflo M; Hethey S; Kaiser O; Kölker S; Wagner R; Witt O; Merkenschlager A; Möckel A; Roser T; Schlump JU; Serfling A; Spiegler J; Milde T; Ziegler A; Syrbe S
Orphanet J Rare Dis; 2019 May; 14(1):96. PubMed ID: 31053163
[TBL] [Abstract][Full Text] [Related]
19. Everolimus compliance and persistence among tuberous sclerosis complex patients with renal angiomyolipoma or subependymal giant cell astrocytoma.
Song X; Said Q; Tran O; Krueger DA; Bissler J
Curr Med Res Opin; 2019 Jun; 35(6):1103-1110. PubMed ID: 30550347
[TBL] [Abstract][Full Text] [Related]
20. Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.
Brakemeier S; Bachmann F; Budde K
Pediatr Nephrol; 2017 Jul; 32(7):1137-1144. PubMed ID: 27585680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]